OrthoPediatrics Corp has a consensus price target of $48.67, established from looking at the 37 latest analyst ratings. The last 3 analyst ratings were released from Truist Securities, Needham, and JMP Securities on May 8, 2024, May 7, 2024, and May 7, 2024. With an average price target of $43.33 between Truist Securities, Needham, and JMP Securities, there's an implied 28.09% upside for OrthoPediatrics Corp from these 3 analyst ratings.
1calculated from analyst ratings published within the last 3 years
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
05/08/2024 | Buy Now | 12.33% | Truist Securities | Samuel Brodovsky | $35 → $38 | Maintains | Hold | Get Alert |
05/07/2024 | Buy Now | 24.15% | Needham | Mike Matson | $37 → $42 | Maintains | Buy | Get Alert |
05/07/2024 | Buy Now | 47.8% | JMP Securities | David Turkaly | → $50 | Reiterates | Market Outperform → Market Outperform | Get Alert |
04/10/2024 | Buy Now | 9.37% | Needham | Mike Matson | → $37 | Reiterates | Buy → Buy | Get Alert |
03/08/2024 | Buy Now | -5.41% | Truist Securities | Samuel Brodovsky | $31 → $32 | Maintains | Hold | Get Alert |
03/07/2024 | Buy Now | 0.5% | Stifel | Rick Wise | $32 → $34 | Maintains | Buy | Get Alert |
03/07/2024 | Buy Now | 9.37% | Needham | Mike Matson | → $37 | Reiterates | Buy → Buy | Get Alert |
03/07/2024 | Buy Now | 47.8% | JMP Securities | David Turkaly | → $50 | Reiterates | Market Outperform → Market Outperform | Get Alert |
01/25/2024 | Buy Now | -8.37% | Truist Securities | Kaila Krum | $39 → $31 | Downgrade | Buy → Hold | Get Alert |
12/22/2023 | Buy Now | 15.28% | Truist Securities | Richard Newitter | $35 → $39 | Maintains | Buy | Get Alert |
12/07/2023 | Buy Now | 47.8% | JMP Securities | David Turkaly | $60 → $50 | Maintains | Market Outperform | Get Alert |
11/08/2023 | Buy Now | 3.46% | Truist Securities | Richard Newitter | $31 → $35 | Maintains | Buy | Get Alert |
11/07/2023 | Buy Now | 9.37% | Needham | Mike Matson | $55 → $37 | Maintains | Buy | Get Alert |
10/04/2023 | Buy Now | 53.71% | BTIG | Ryan Zimmerman | $59 → $52 | Maintains | Buy | Get Alert |
09/01/2023 | Buy Now | 77.36% | JMP Securities | David Turkaly | → $60 | Reiterates | Market Outperform → Market Outperform | Get Alert |
08/02/2023 | Buy Now | 50.75% | Truist Securities | Richard Newitter | $57 → $51 | Maintains | Buy | Get Alert |
08/01/2023 | Buy Now | 77.36% | JMP Securities | David Turkaly | → $60 | Reiterates | Market Outperform → Market Outperform | Get Alert |
08/01/2023 | Buy Now | 62.58% | Needham | Mike Matson | → $55 | Reiterates | Buy → Buy | Get Alert |
05/02/2023 | Buy Now | 62.58% | Needham | Mike Matson | $51 → $55 | Maintains | Buy | Get Alert |
05/02/2023 | Buy Now | 77.36% | JMP Securities | David Turkaly | → $60 | Reiterates | → Market Outperform | Get Alert |
04/17/2023 | Buy Now | 50.75% | Needham | Mike Matson | → $51 | Maintains | Buy | Get Alert |
04/17/2023 | Buy Now | 68.49% | Truist Securities | Richard Newitter | $53 → $57 | Maintains | Buy | Get Alert |
03/01/2023 | Buy Now | 50.75% | Needham | Mike Matson | $50 → $51 | Maintains | Buy | Get Alert |
01/31/2023 | Buy Now | 65.53% | Truist Securities | Richard Newitter | $47 → $56 | Maintains | Buy | Get Alert |
01/10/2023 | Buy Now | 47.8% | Stifel | Rick Wise | $52 → $50 | Maintains | Buy | Get Alert |
11/02/2022 | Buy Now | 77.36% | JMP Securities | David Turkaly | $70 → $60 | Maintains | Market Outperform | Get Alert |
11/01/2022 | Buy Now | 47.8% | Needham | Mike Matson | $59 → $50 | Maintains | Buy | Get Alert |
10/17/2022 | Buy Now | 53.71% | Truist Securities | Kaila Krum | $66 → $52 | Maintains | Buy | Get Alert |
08/05/2022 | Buy Now | 95.09% | Truist Securities | Kaila Krum | $51 → $66 | Maintains | Buy | Get Alert |
07/18/2022 | Buy Now | 80.31% | BTIG | Ryan Zimmerman | $65 → $61 | Maintains | Buy | Get Alert |
The latest price target for OrthoPediatrics (NASDAQ: KIDS) was reported by Truist Securities on May 8, 2024. The analyst firm set a price target for $38.00 expecting KIDS to rise to within 12 months (a possible 12.33% upside). 18 analyst firms have reported ratings in the last year.
The latest analyst rating for OrthoPediatrics (NASDAQ: KIDS) was provided by Truist Securities, and OrthoPediatrics maintained their hold rating.
There is no last upgrade for OrthoPediatrics.
The last downgrade for OrthoPediatrics Corp happened on January 25, 2024 when Truist Securities changed their price target from $39 to $31 for OrthoPediatrics Corp.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of OrthoPediatrics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for OrthoPediatrics was filed on May 8, 2024 so you should expect the next rating to be made available sometime around May 8, 2025.
While ratings are subjective and will change, the latest OrthoPediatrics (KIDS) rating was a maintained with a price target of $35.00 to $38.00. The current price OrthoPediatrics (KIDS) is trading at is $33.83, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.